Sirtex Medical (ASX:SRX) said yesterday that the National Comprehensive Cancer Network has recommended the company’s radioactive microspheres in its Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. The NCCN panel uniformly agreed that selective internal radiation therapy with yttrium-90 microspheres is an option for patients with metastatic, chemotherapy resistant colorectal cancer.
The recommendation was supported by the More retrospective analysis study, which included 600 patients with colorectal cancer. The data suggested that selective internal radiation therapy using Y-90 microspheres is safe and effective in patients who have failed multiple lines of chemotherapy.
Get the full story at our sister site, Drug Delivery Business News.
The post National cancer group recommends Sirtex’s microspheres for metastatic colorectal cancer appeared first on MassDevice.